These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29339684)

  • 1. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?].
    Öngen Z
    Turk Kardiyol Dern Ars; 2018 Jan; 46(1):1-6. PubMed ID: 29339684
    [No Abstract]   [Full Text] [Related]  

  • 2. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.].
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Peticevic M; Roffi M; Steg PG; Windecker S; Zamorano JL
    Kardiol Pol; 2017; 75(12):1217-1299. PubMed ID: 29251754
    [No Abstract]   [Full Text] [Related]  

  • 3. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL; Levine GN;
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):34-78. PubMed ID: 29045581
    [No Abstract]   [Full Text] [Related]  

  • 4. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL; Levine GN; ; ;
    Eur Heart J; 2018 Jan; 39(3):213-260. PubMed ID: 28886622
    [No Abstract]   [Full Text] [Related]  

  • 5. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.
    Collet JP; Roffi M; Byrne RA; Costa F; Valgimigli M; ; ;
    Eur Heart J; 2018 Jan; 39(3):e1-e33. PubMed ID: 29088328
    [No Abstract]   [Full Text] [Related]  

  • 6. 2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
    Jeppsson A; Petricevic M; Kolh P; Valgimigli M
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):3-4. PubMed ID: 29028979
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease-a review.
    Alber HF; Huber K
    Wien Klin Wochenschr; 2018 Dec; 130(23-24):694-697. PubMed ID: 30030604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease.
    Mauri L; Smith SC
    JAMA Cardiol; 2016 Sep; 1(6):733-4. PubMed ID: 27548911
    [No Abstract]   [Full Text] [Related]  

  • 9. Aspirin in coronary artery disease: an appraisal of functions and limitations.
    Würtz M
    Dan Med J; 2015 Apr; 62(4):B5011. PubMed ID: 25872543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
    Degrauwe S; Iglesias JF
    Rev Med Suisse; 2016 May; 12(520):1022-6, 1028-34. PubMed ID: 27424342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease.
    Zeidner JF; Frishman WH; Lerner RG
    Cardiol Rev; 2008; 16(5):250-9. PubMed ID: 18708826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL
    Rev Esp Cardiol (Engl Ed); 2018 Jan; 71(1):42. PubMed ID: 29277234
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
    Bonello L; Lemesle G; De Labriolle A; Barragan P; Camoin-Jau L; Paganelli F
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1525-32. PubMed ID: 19954314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
    Ignjatovic V; Pavlovic S; Miloradovic V; Andjelkovic N; Davidovic G; Djurdjevic P; Stolic R; Iric-Cupic V; Simic I; Ignjatovic VD; Petrovic N; Smiljanic Z; Zdravkovic V; Simovic S; Jovanovic D; Nesic J
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):44-52. PubMed ID: 25868659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
    Eur Heart J; 2018 Jun; 39(22):2089. PubMed ID: 29087454
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
    Tello-Montoliu A; Ueno M; Angiolillo DJ
    Future Cardiol; 2011 May; 7(3):381-402. PubMed ID: 21627478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.